Microcap Ledger Silence Therapeutics plc $SLN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- London
- Shares outstanding
- 141,740,037 [10-Q 2026-08-10]
What the company doesAI summary of filing
Silence Therapeutics plc is a clinical-stage biotechnology company developing siRNA (short interfering RNA) therapeutics designed to silence disease-associated genes, primarily targeting delivery to liver cells using its proprietary mRNAi GOLD platform. The company generates revenue through milestone payments and royalties from collaboration agreements, most notably with AstraZeneca, but has not yet commercialized any products. Its pipeline includes candidates in Phase 2 development for rare blood disorders, Phase 3-ready candidates for cardiovascular disease, and earlier-stage programs for metabolic and obesity-related conditions, with clinical trials ongoing and regulatory approvals pending. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $422.0K | −$27.23M | −$14.09M | $72.05M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $559.0K | −$88.61M | −$62.27M | $11.28M | [10-K 2026-03-05] |
| FY ended Dec 2024 | $43.26M | −$45.31M | −$67.64M | $121.33M | [10-K 2026-03-05] |
- Quarterly cash burn
- −$7.04M
- Cash runway Estimate
- ~30.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-01-31 | 141,674,074 | [10-K 2025-02-27] |
| 2025-04-21 | 141,690,850 | [10-K/A 2025-04-30] |
| 2025-04-30 | 141,690,850 | [10-Q 2025-05-08] |
| 2025-07-31 | 141,701,848 | [10-Q 2025-08-07] |
| 2025-10-30 | 141,701,848 | [10-Q 2025-11-06] |
| 2026-01-31 | 141,701,848 | [10-K 2026-03-05] |
| 2026-04-30 | 141,703,840 | [10-Q 2026-05-07] |
| 2026-07-31 | 141,740,037 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2026-05-18; declared effective 2026-05-27 [S-3 2026-05-18]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 8-K | Material agreement entered; Other events |
| 2026-08-12 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-10 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-10 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-07-16 | 8-K | Director or officer change |
| 2026-07-08 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-23 | 8-K | Regulation FD disclosure |
| 2026-06-16 | 8-K | Shareholder vote results |
Alerts for $SLN
Email me when Silence Therapeutics plc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.